January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
56 citations,
April 1998 in “Steroids” Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.
50 citations,
April 2010 in “Biology direct” Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
January 2016 in “Springer eBooks” The document concludes that there are various causes and treatments for hair loss, with hair transplantation being a notable option.
28 citations,
August 2011 in “Journal of The American Academy of Dermatology” Early hair loss may indicate prostate issues.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
224 citations,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
29 citations,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
October 2022 in “Biomedicines” Finasteride in male rats causes liver and metabolic issues in their offspring.
20 citations,
May 2011 in “Cancer Biology & Therapy” Finasteride may improve prostate cancer treatment outcomes.
12 citations,
January 1998 in “Endocrine journal” Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
62 citations,
April 2004 in “Expert Opinion on Pharmacotherapy” Finasteride effectively treats male pattern baldness, improving hair growth and density.
17 citations,
March 2016 in “Liver international” Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.
29 citations,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
20 citations,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
5 citations,
May 2018 in “Statistics in Medicine” Model improves accuracy in predicting hair loss effects.
17 citations,
June 2018 in “Sexual Medicine Reviews” The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.
51 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
92 citations,
November 2003 in “The Journals of Gerontology” Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.
14 citations,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
23 citations,
January 2001 in “Chemical & Pharmaceutical Bulletin” New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.
66 citations,
January 2001 in “Vitamins and hormones” Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.
489 citations,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
72 citations,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
60 citations,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
18 citations,
January 2001 in “Annual Reports in Medicinal Chemistry” Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.
57 citations,
September 2017 in “Journal of controlled release” Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.
April 2015 in “Journal of Evolution of Medical and Dental Sciences” People with autoimmune skin diseases often have hearing problems and should get their hearing checked early.